← brief for 2026-08-13 · Slowing decline
Advances in Cardiovascular Pharmacotherapy. IX. Protection Against Major Adverse Cardiovascular Events by Glucagon-like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus and Obesity.
Key takeaways
A review of GLP-1 RA use in patients with type 2 diabetes and obesity. It found no difference in cardiovascular or renal outcomes.
Who did this work
Pagel PS · Hang D · Freed JK · Crystal GJ
Source
Article · PubMed, the drug frontier · 2026 Jul 19
https://pubmed.ncbi.nlm.nih.gov/42580924/